$BVS News

Canaccord Genuity Maintains Buy on Bioventus, Raises Price Target to $19

Cantor Fitzgerald Reiterates Overweight on Bioventus, Maintains $15 Price Target

Bioventus (BVS) Q2 2026 Earnings Call Transcript

Bioventus (BVS) Stock Still Looks Like A Bargain On Earnings

The Bull Case For Bioventus (BVS) Could Change Following Its Q2 Earnings Surge And Reaffirmed 2026 Guidance

Is Bioventus (BVS) Stock Undervalued Right Now?

Bioventus Inc. Q2 2026 Earnings Call Summary

Bioventus Inc (BVS) (Q2 2026) Earnings Call Highlights: Strategic Review and Strong HA Growth ...

Bioventus Inc. 2026 Q2 - Results - Earnings Call Presentation

Bioventus Q2 Earnings Call Highlights

Bioventus Inc. (BVS) Q2 2026 Earnings Call Transcript

Bioventus (NASDAQ:BVS) Falls After Q2 Revenue Miss, Launches Strategic Review

Bioventus Reports Second Quarter Financial Results

Bioventus Q2 Adj. EPS $0.22, Inline, Sales $153.208M Miss $155.640M Estimate

Bioventus Affirms FY2026 Adj EPS Guidance of $0.75-$0.79 vs $0.78 Est; Affirms FY2026 Sales Guidance of $600.000M-$610.000M vs $605.756M Est

Bioventus (BVS) to Report Q2 Results: Wall Street Expects Earnings Growth

Bioventus to Report Second Quarter of Fiscal Year 2026 Financial Results on August 5, 2026

Does Bioventus (BVS) Have the Potential to Rally 28.92% as Wall Street Analysts Expect?

Bioventus (BVS) Upgraded to Buy: Here's Why

Should Value Investors Buy Bioventus (BVS) Stock?